FDA Approved: VITRAKVI — Original Application (Loxo Oncology, Inc.)

View source ↗

Summary

The FDA granted original approval of VITRAKVI (larotrectinib) as a tissue-agnostic treatment for cancers with an NTRK gene fusion, marking its first approval fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion-positive Cancers

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

ORIG AP for VITRAKVI (LAROTRECTINIB)